Disruptive Pharma AB
Hans Thor is an experienced analytical chemist with a career spanning over three decades in the pharmaceutical and materials sectors. Currently serving as a Senior Analytical Chemist at Disruptive Pharma AB since November 2021, Hans previously held similar positions at Novavax AB and Disruptive Materials AB. Prior experience includes a long tenure at Fresenius Kabi as an analytical chemist and a role as a laboratory investigator at the Medical Products Agency Läkemedelsverket. Hans began their career as a laboratory engineer at Pharmacia Corporation. Educationally, Hans holds a Bachelor's degree in Chemistry from Uppsala University, obtained between 1984 and 1987.
Disruptive Pharma AB
Disruptive Pharma is a pharmaceutical company that develops novel drug products by applying a unique drug delivery technology. We develop selected drug products based on our proprietary drug delivery platform, the pharma-grade mesoporous magnesium carbonate (Pharma-MMC). The Disruptive Pharma company has offices in both Uppsala (HQ) and Stockholm. By a clever combination of already approved active pharmaceutical ingredients (APIs) with Pharma-MMC platform, several unique opportunities to realize highly valuable therapeutically equivalent or improved drug products emerges. The Pharma-MMC drug delivery technology can be used to create amorphous solid dispersions of the drug, hence increasing its dissolution and the body’s ability to absorb the drug, and may be used to rescue particularly difficult drugs or to enable novel product formulations Disruptive Pharma is a spin-out from the company Disruptive Materials that is located in Uppsala. The company is well-positioned to exploit its pioneering discovery of a unique mesoporous magnesium carbonate (MMC) material. Up until breakthrough discovery by the group of Professor Maria Strømme in 2012, commercialized by Disruptive Materials AB in 2013.